Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ondansetron Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg

NCT00648583
View directory record Official record
Conditions
Healthy
Interventions
Ondansetron Tablets 24 mg, Zofran® Tablets 24 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Jul 22, 2026, 8:24 AM EDT
Withdrawn Phase 3 Interventional

A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

NCT00891761
View directory record Official record
Conditions
Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting, Solid Tumor Cancer
Interventions
Dexamethasone, IV casopitant (placebo), IV casopitant (active), Ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Robbinsdale, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Jul 22, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder

NCT02354703
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Jul 22, 2026, 8:24 AM EDT
Withdrawn Not applicable Interventional

Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting

NCT00699894
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
aprepitant 40 mg, ondansetron 4 mg
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 25 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2013 · Synced Jul 22, 2026, 8:24 AM EDT
Completed Not applicable Interventional Results available

CSF Pharmacokinetics of Ondansetron

NCT02901054
View directory record Official record
Conditions
Pain
Interventions
Ondansetron
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Jul 22, 2026, 8:24 AM EDT
Terminated Phase 3 Interventional Results available

Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

NCT05065567
View directory record Official record
Conditions
Cyclic Vomiting Syndrome
Interventions
Droperidol, Haloperidol, Ondansetron 8mg
Drug
Lead sponsor
Corewell Health South
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jul 22, 2026, 8:24 AM EDT
Completed Early Phase 1 Interventional

Value of Ondansetron Medication vs Inhaled Isopropyl Therapy in the Emergency Department (VOMIITED)

NCT03125811
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Inhaled Isopropyl Alcohol (IPA), Oral Dissolvable Tablet Zofran (ondansetron)
Other · Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Jul 22, 2026, 8:24 AM EDT
Completed No phase listed Observational Results available

Ondansetron and the QT Interval In Adult Emergency Department Patients

NCT01759420
View directory record Official record
Conditions
Ondansetron
Interventions
Ondansetron
Drug
Lead sponsor
C.R.Darnall Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Fort Hood, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Jul 22, 2026, 8:24 AM EDT
Completed Phase 2 Interventional

Post-Operative Nausea And Vomiting Study In Female Patients

NCT00274690
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
11
States / cities
San Francisco, California • Melbourne, Florida • West Palm Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Jul 22, 2026, 8:24 AM EDT
Recruiting Phase 3 Interventional

Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

NCT06588413
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplantation
Interventions
Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jul 22, 2026, 8:24 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Ondansetron Use for Preventing Pruritus in Patients Undergoing Cesarean Section

NCT06297499
View directory record Official record
Conditions
Pruritus Caused by Drug
Interventions
Ondansetron 8mg
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Jul 22, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)

NCT00967499
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Ondansetron, Palonosetron
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Phoenix, Arizona • Laguna Hills, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Jul 22, 2026, 8:24 AM EDT
Completed Phase 2 Interventional

Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial

NCT00678457
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Ondansetron, Olanzapine, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2009 · Synced Jul 22, 2026, 8:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tariquidar-ondansetron Combination in Neuropathic Pain

NCT04603066
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Ondansetron 16 mg with Tariquidar, Ondansetron 16 mg with Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jul 22, 2026, 8:24 AM EDT
Completed Not applicable Interventional Results available

EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron

NCT02618343
View directory record Official record
Conditions
Nausea
Interventions
IPA, Ondansetron
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Jul 22, 2026, 8:24 AM EDT
Terminated Phase 4 Interventional Results available

Comparative Study of Superficial Cervical Plexus Block and Nerve of Arnold Block and Incidence of PONV for Inner Ear Surgery

NCT02724033
View directory record Official record
Conditions
Anesthesia, Pediatrics, Surgery
Interventions
regional nerve block, Antiemetic
Procedure · Drug
Lead sponsor
Indiana University
Other
Eligibility
1 Year to 18 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Jul 22, 2026, 8:24 AM EDT
Completed Not applicable Interventional

Ondansetron VS Doxylamine and Pyridoxine in Treating Nausea of Pregnancy

NCT01668069
View directory record Official record
Conditions
Vomiting of Pregnancy
Interventions
Ondansetron
Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 90 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Jul 22, 2026, 8:24 AM EDT
Completed Phase 4 Interventional

Examining the Effect of Ondansetron on Bowel Prep Success

NCT05439772
View directory record Official record
Conditions
Abdominal Pain, Inflammatory Bowel Diseases, Eosinophilic Gastroenteritis, Diarrhea, Hematochezia, Weight Loss
Interventions
Ondansetron
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
2 Years to 20 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 22, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

NCT01442376
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
Up to 16 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Little Rock, Arkansas • Duarte, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Jul 22, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women

NCT01965704
View directory record Official record
Conditions
Narcotic Addiction, Neonatal Abstinence Syndrome
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 45 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
8
States / cities
San Francisco, California • San Jose, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Jul 22, 2026, 8:24 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers

NCT03809234
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Ondansetron 8mg with Saline & Tariquidar, Ondansetron 16mg with Saline & Tariquidar
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Jul 22, 2026, 8:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Matching Genotypes and Serotonergic Medications for Alcoholism

NCT01113164
View directory record Official record
Conditions
Alcoholism
Interventions
Ondansetron and Sertraline
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Jul 22, 2026, 8:24 AM EDT
Completed Not applicable Interventional Results available

Effect of Ondansetron for Withdrawal Symptoms

NCT00695864
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
Ondansetron and Placebo crossover
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Jul 22, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

NCT01395901
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
Up to 16 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Florence, Alabama • Sheffield, Alabama • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Jul 22, 2026, 8:24 AM EDT